Purdue Pharma L.P. et al. v. Teva Pharmaceuticals USA, Inc.; Purdue Pharma L.P. et al. v. Teva Pharmaceuticals USA, Inc.
December 23, 2014
Case Number: 1:13-cv-04606-SHS; 1:14-cv-02357-SHS
Teva settled with plaintiffs in two matters concerning abuse-proofing pharmaceutical dosage forms. One settlement covered U.S. Patents Nos. Patents U.S. Patent No. 8,309,060 (“Abuse-proofed dosage form”) and 8,337,888 (“Pharmaceutical formulation containing gelling agent”). The second settlement covered U.S. Patent No. 6,488,963 (“Hot-melt extrudable pharmaceutical formulation”). Teva acknowledged the patents’ validity and enforceability, and further agreed that, but for an undisclosed license agreement, its oxycodone products would infringe the patents.
